Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Akamis Bio
Private Company Edition: While Coya Therapeutics raised $15.25m in the final initial public offering in the US last year, Apnimed stayed private raising $80m in a series C extension and Metagenomi extended its series B by $100m to total $275m.
The development of oncolytic virus therapy has gained momentum over the past decade, due to its relatively safe mode of action and potential to enhance existing treatment options. A third of cancer vaccines in development are now oncolytic viruses, which are being developed for about 40 different types of cancer. In Vivo takes a closer look at therapies in development to see what the future holds for this promising therapy.
Paying €210m for a company that only has preclinical programs may seem steep but BI is clearly impressed with the progress being made by its Austrian partner's lead candidate.
Transgene's CEO discusses its immunotherapy pipeline, coming catalysts, and why the French biotech may soon be swept up by growing interest in oncolytic viruses.
- Gene Therapy, Cell Therapy
- Large Molecule
- Other Names / Subsidiaries
- Hybrid Biosystems Ltd.
- Myotec Therapeutics Ltd.
- PsiOxus Therapeutics, Ltd.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.